DDMAC warns Abbott on Kaletra DVD

Share this article:
FDA warned Abbott about a patient testimonial DVD for its HIV drug Kaletra, starring Earvin “Magic” Johnson.
The DVD, I Know What's Important, minimizes the risks, overstates efficacy and includes unsubstantiated claims, DDMAC said in a warning letter dated July 14.

At the beginning of the DVD, Johnson answers questions in an interview-style format, although “the only risk information included during the interview are a brief acknowledgement by Johnson that he experiences ‘fatigue sometimes,'” with other risk information superimposed in text, according to the letter.

DDMAC contends that the interview portion omits “any discussion of serious risks,” and relegates that information to the end, “where it is unlikely to draw the viewer's attention, and is displayed as a running telescript.”

Additionally, DDMAC took issue with several statements made by Johnson during the interview that overstated the efficacy of Kaletra: “While these statements may be an accurate reflection of Magic Johnson's own experience…this promotional testimonial suggests that Kaletra has been shown to allow all or most antiretroviral treatment-experienced individuals…to live a ‘normal life'…for five or more years.” Evidence is lacking for that claim, the letter said. The DVD also featured outdated product labeling.

DDMAC's warning letter to Abbott follows an untitled letter on the subject of Kaletra promotion in 2004—that letter questioned a print ad and poster that overstated effectiveness and omitted risk information.

Johnson has been associated with Abbott and Kaletra for several years as a spokesman, having previously served as a pitchman for GlaxoSmithKline's Combivir.

In 2008, Shire was warned over a patient testimonial video featuring celebrity Ty Pennington, after he discussed his experience with Adderall XR —and inadvertently expanded the drug's indication.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.